The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and Prevention
Open accessAbstract
Multidrug-resistant bacteria are the cause of an increasing number of deadly pulmonary infections. Because there is currently a paucity of novel antibiotics, phage therapy--the use of specific viruses that infect bacteria--is now more frequently being considered as a potential treatment for bacterial infections. Using a mouse lung-infection model caused by a multidrug resistant Pseudomonas aeruginosa mucoid strain isolated from a cystic fibrosis patient, we evaluated bacteriophage treatments. New bacteriophages were isolated from environmental samples and characterized. Bacteria and bacteriophages were applied intranasally to the immunocompetent mice. Survival was monitored and bronchoalveolar fluids were analysed. Quantification of bacteria, bacteriophages, pro-inflammatory and cytotoxicity markers, as well as histology and immunohistochemistry analyses were performed. A curative treatment (one single dose) administrated 2 h after the onset of the infection allowed over 95% survival. A four-day preventive treatment (one single dose) resulted in a 100% survival. All of the parameters measured correlated with the efficacy of both curative and preventive bacteriophage treatments. We also showed that in vitro optimization of a bacteriophage towards a clinical strain improved both its efficacy on in vivo treatments and its host range on a panel of 20 P. aeruginosa cystic fibrosis strains. This work provides an incentive to develop clinical studies on pulmonary bacteriophage therapy to combat multidrug-resistant lung infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
High abundance of viruses found in aquatic environments
Bergh, Ø., BØrsheim, K. Y., Bratbak, G., & Heldal, M. (1989) · Nature · doi:10.1038/340467a0 · Cited by 1,649
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Jones, R. N. (2010) · Clinical Infectious Diseases · doi:10.1086/653053 · Cited by 716 · cited 1×
“Pseudomonas aeruginosa is the second most common pathogen responsible for hospital-acquired bacterial pneumonia as well as ventilator-associated pneumonia, and the first causative agent of morbidity and mortality in cystic fibrosis (CF) patients [1,2].”
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
Summers, W. C. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.437 · Cited by 474
Willner, D., Furlan, M., Haynes, M., Schmieder, R., Angly, F. E., Silva, J., Tammadoni, S., Nosrat, B., Conrad, D., & Rohwer, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007370 · Cited by 441 · cited 1×
“Recently, a metagenomic analysis of viral DNA present in the lungs of CF patients identified over 100 different viral genomes, and this was considered to be a low diversity compared with other environments [21].”
Smith, H. W., & Huggins, M. B. (1983) · Microbiology · doi:10.1099/00221287-129-8-2659 · Cited by 436
The prospect for bacteriophage therapy in Western medicine
Merril, C. R., Scholl, D., & Adhya, S. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1111 · Cited by 367
Fu, W., Forster, T., Mayer, O., Curtin, J. J., Lehman, S. M., & Donlan, R. M. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00669-09 · Cited by 362
Preventing biofilms of clinically relevant organisms using bacteriophage
Donlan, R. M. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2008.11.002 · Cited by 345
Bacteriophages Can Treat and Prevent Pseudomonas aeruginosa Lung Infections
Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Balloy, V., & Touqui, L. (2010) · The Journal of Infectious Diseases · doi:10.1086/651135 · Cited by 304
Self-citationBacteriophage and their lysins for elimination of infectious bacteria
O'Flaherty, S., Ross, R. P., & Coffey, A. (2009) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2009.00176.x · Cited by 272
Phage therapy experience at the Eliava Institute
Kutateladze, M., & Adamia, R. (2008) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2008.06.023 · Cited by 258
Nordmann, P., Naas, T., Fortineau, N., & Poirel, L. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.07.004 · Cited by 206
The epidemiology of antibiotic resistance
Gould, I. M. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.016 · Cited by 174
Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis
GOMEZ, M., & PRINCE, A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.12.005 · Cited by 172
Goure, J., Pastor, A., Faudry, E., Chabert, J., Dessen, A., & Attree, I. (2004) · Infection and Immunity · doi:10.1128/iai.72.8.4741-4750.2004 · Cited by 171
Bacteriophage Therapy in Humans
Sulakvelidze, A., & Kutter, E. (2004) · Bacteriophages · doi:10.1201/9780203491751.ch14 · Cited by 170
Efficacy of Bacteriophage Therapy in a Model ofBurkholderia cenocepaciaPulmonary Infection
Carmody, L. A., Gill, J. J., Summer, E. J., Sajjan, U. S., Gonzalez, C. F., Young, R., & LiPuma, J. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/649227 · Cited by 154
Glonti, T., Чанішвілі, Н., & Taylor, P. W. (2009) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2009.04469.x · Cited by 140
Boulanger, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-565-1_13 · Cited by 137
Bacteriophage therapy for the treatment of infections.
Górski, A., Międzybrodzki, R., Borysowski, J., et al. (2009) · PubMed · Cited by 129
TLRs 2 and 4 Are Not Involved in Hypersusceptibility to Acute Pseudomonas aeruginosa Lung Infections
Ramphal, R., Balloy, V., Huerre, M., Si‐Tahar, M., & Chignard, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3927 · Cited by 92
Self-citationBacterial viruses as human vaccines?
Clark, J. R., & March, J. B. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.4.463 · Cited by 89
Bacteriophage interactions with phagocytes and their potential significance in experimental therapy
Kurzępa, A., Dąbrowska, K., Skaradziński, G., & Górski, A. (2009) · Clinical and Experimental Medicine · doi:10.1007/s10238-008-0027-8 · Cited by 48
Bacterial viruses against viruses pathogenic for man?
Międzybrodzki, R., Fortuna, W., Weber‐Dąbrowska, B., & Górski, A. (2005) · Virus Research · doi:10.1016/j.virusres.2005.01.009 · Cited by 43
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.014 · Cited by 1,212
Wittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
Bacteriophage-encoded depolymerases: their diversity and biotechnological applications
Pires, D. P., Oliveira, H., Melo, L. D. R., Sillankorva, S., & Azeredo, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7247-0 · Cited by 517
Metadata
- Authors
- Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., & Debarbieux, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-15
- Volume
- 6
- Issue
- 2
- Pages
- e16963
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2075138421
- Cited by
- 275
- References
- 27
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.